NCT04858568 - Immune Responses to COVID-19 Vaccination in Lymphoma Patients | Biotech Hunter

Enrollment

592

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

January 31, 2024

Conditions

Classical Hodgkin LymphomaDiffuse Large B Cell LymphomaPrimary Mediastinal B Cell LymphomaHigh-grade B-cell LymphomaBurkitt LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLymphoplasmacytic LymphomaNodular Lymphocyte Predominant Hodgkin LymphomaPeripheral T-cell Lymphoma

Trial Locations (9)

MK42 9DJ

Bedfordshire Hospitals NHS Foundation Trust, Bedford

PO6 3LY

Portsmouth Hospitals University NHS Trust, Portsmouth

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

HR1 2ER

Wye Valley NHS Trust, Hereford

LE1 5WW

University Hospitals of Leicester NHS Trust, Leicester

NR4 7UY

Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

OX3 7LE

Oxford University Hospitals NHS Foundation Trust, Oxford

NE7 7DN

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors

lead

University Hospital Southampton NHS Foundation Trust

OTHER